Nestle launches website for individuals on weight loss drugs
June 25 (Reuters) -Nestle's NESN.S health unit on Tuesday launched a web platform to provide nutritional support for individuals on weight loss programs, including those using GLP-1 medications.
Nestle Health Science said the website will address specific needs such as preserving lean muscle mass, supporting gut health, and offering personalized diet assistance.
WHY IT'S IMPORTANT
As more people use GLP-1 drugs for weight control, several telehealth companies have started offering services to support these individuals.
In June,Kroger Health, the division of the grocery chain Kroger K.N that operates pharmacies and clinics across the U.S., revamped its weight management program to offer patients access to medical treatments such as Wegovy, Zepbound and others.
Health and wellness platform Hims & Hers HIMS.N Health in May also addedcompounded versions of GLP-1 injections to its comprehensive weight loss portfolio
CONTEXT
GLP-1 medications have recently become popular and are in strong demand in the U.S. These drugs, including Novo Nordisk's NOVOb.CO Ozempic and Wegovy, were initially developed to treat type 2 diabetes but also help with weight loss by suppressing appetite and promoting fullness.
However, there have been intermittent shortages over the past year, with makers such as Novo Nordisk and Eli Lilly LLY.N, which makes Mounjaro racing to ramp up supply.
The growing use of these drugs has led experts to project annualglobal sales of about $150 billion by the early 2030s.
Reporting by Ananya Mariam Rajesh in Bengaluru; Editing by Tasim Zahid
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
